Michael J. Hall, MD, MS

Pancreatic cancer with&nbsp;<em>BRCA1</em>and&nbsp;<em>BRCA2&nbsp;</em>mutations has shown positive responses to the PARP inhibitor olaparib in preliminary trials.&nbsp;